SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: 2020-05-04 | Period of Report: 2020-05-01 SEC Accession No. 0001127602-20-015199

(HTML Version on secdatabase.com)

REPORTING OWNER

Andres Juan

CIK:1760670

Type: 4 | Act: 34 | File No.: 001-38753 | Film No.: 20845251

Mailing Address C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139

ISSUER

Moderna, Inc.

CIK:1682852| IRS No.: 813467528 | State of Incorp.:DE | Fiscal Year End: 1231 SIC: 2836 Biological products, (no disgnostic substances)

Mailing Address CAMBRIDGE MA 02139

Business Address 200 TECHNOLOGY SQUARE 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 6177146500

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Expires:	02/28/2011									
Estimated average burden										
hours per response	0.5									

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres Andres Juan	s of Reporting Perso	on *	Issuer Name and Ticker or Trading Symbol Moderna, Inc. [MRNA]	Relationship of Reporting Person(s) to Issuer (Check all applicable) Director				
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/01/2020	X_ Officer (give title Other (specify below) below) See remarks				
C/O MODERNA	, INC., 200 TECH	INOLOGY						
SQUARE								
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing (Check applicable line)X Form Filed by One Reporting Person				
CAMBRIDGE, MA 02139			_	Form Filed by More than One Reporting Person				
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/ Day/Year)	2A. Deemed Execution Date, if any (Month/ Day/Year)	3. Transaction Code (Instr. 8)		1 ' ' ' ' ' '			5. Amount of Securities Beneficially Owned	Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	٧	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)		
Common Stock	05/01/2020		<u>M</u> (1)		25,000	A	\$12.21	25,000	D		
Common Stock	05/01/2020		<u>S</u> (1)		6,298	D	\$46.91 ⁽²⁾	18,702	D		
Common Stock	05/01/2020		<u>s</u> (1)		10,784	D	\$47.82 ⁽³⁾	7,918	D		
Common Stock	05/01/2020		<u>s</u> (1)		3,984	D	\$48.87 ^(<u>4</u>)	3,934	D		
Common Stock	05/01/2020		<u>s</u> (1)		3,934	D	\$49.69 ^(<u>5</u>)	0	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/ Day/Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transaction Code (Instr. 8)		-		6. Date Exercisable and Expiration Date (Month/ Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of Derivative	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Stock Option (Right to Buy)	\$12.21	05/01/2020		<u>M</u> (1)			25,000	(<u>6</u>)	08/29/2027	Common Stock	25,000	\$ 0	812,322	D	

Explanation of Responses:

- 1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$46.32 to \$47.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$47.33 to \$48.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$48.34 to \$49.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$49.36 to \$50.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 6. 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer

Signatures

/s/ Lori Henderson, as Attorney-in-Fact

05/04/2020

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.